1. Scrip
  2. >>Archive

Argos Aims To Automate Cell-Based Cancer Therapy

 
• By Deborah Erickson

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

“There is a fine line between tenacity and insanity,” says Jeff Abbey, president and CEO of Durham, NC-based Argos Therapeutics Inc. since February 2010. He has held several roles at the firm including VP of business development and chief business officer. Abbey claims to have attained some intimate understanding of the abyss in the course of his tenure, and no wonder. Argos is intent on creating the first cell-based, personalized cancer therapy to qualify as both a clinical and commercial success. The company has been working toward this goal since 1997, and is at last nearing the finish line.

Argos' Arcelis technology platform has evolved along with understanding that dendritic cells are the “teaching” cells of the immune system. Dendritic cells scavenge diseased cells and foreign invaders that they...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.